XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells

• Published in: Cancer research (Chicago, Ill.) Vol. 84; no. 1; pp. 101 - 117
• Main Authors: Marullo, Rossella, Rutherford, Sarah C, Revuelta, Maria V, Zamponi, Nahuel, Culjkovic-Kraljacic, Biljana, Kotlov, Nikita, Di Siervi, Nicolás, Lara-Garcia, Juan, Allan, John N, Ruan, Jia, Furman, Richard R, Chen, Zhengming, Shore, Tsiporah B, Phillips, Adrienne A, Mayer, Sebastian, Hsu, Jingmei, van Besien, Koen, Leonard, John P, Borden, Katherine L B, Inghirami, Giorgio, Martin, Peter, Cerchietti, Leandro
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 02.01.2024
• Subjects: Clinical Trial Results; Dna Damage And Repair; Hematological Cancers; Translational Cancer Biology
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-23-1992

Exportin-1 (XPO1), the main soluble nuclear export receptor in eukaryotic cells, is frequently overexpressed in diffuse large B-cell lymphoma (DLBCL). A selective XPO1 inhibitor, selinexor, received approval as single agent for relapsed or refractory (R/R) DLBCL. Elucidating the mechanisms by which XPO1 overexpression supports cancer cells could facilitate further clinical development of XPO1 inhibitors. We uncovered here that XPO1 overexpression increases tolerance to genotoxic stress, leading to a poor response to chemoimmunotherapy. Upon DNA damage induced by MYC expression or exogenous compounds, XPO1 bound and exported EIF4E and THOC4 carrying DNA damage repair mRNAs, thereby increasing synthesis of DNA damage repair proteins under conditions of increased turnover. Consequently, XPO1 inhibition decreased the capacity of lymphoma cells to repair DNA damage and ultimately resulted in increased cytotoxicity. In a phase I clinical trial conducted in R/R DLBCL, the combination of selinexor with second-line chemoimmunotherapy was tolerated with early indication of efficacy. Overall, this study reveals that XPO1 overexpression plays a critical role in the increased tolerance of cancer cells to DNA damage while providing new insights to optimize the clinical development of XPO1 inhibitors. XPO1 regulates the dynamic ribonucleoprotein nuclear export in response to genotoxic stress to support tolerance and can be targeted to enhance the sensitivity of cancer cells to endogenous and exogenous DNA damage. See related commentary by Knittel and Reinhardt, p. 3.